Abstract :
Background:
Insulin resistance plays an important role in pathogenesis of NAFLD. Adiponectin hasα reduces insulin sensitivity and has proinflammatoryα inhibitor,
Methods:
and secondary causes of NASH excluded. All patients had persistently elevated ALT (>1.5 times for more
than 6 months, after dietary treatment for 2 months) were randomized into 2 groups. The first group was given
pentoxifylline at a dosage of 400 mg t.i.d. plus dietary treatment and the second group was given placebo with
dietary treatment for 6 months. The changes in ALT, AST, insulin resistance index (homeostatic metabolic assessment
insulin resistance (HOMA IR) index, waist/hip ratio), TNF-
of treatment were compared between 2 groups.
Thirty-two patients had biopsy-confirmed NASH and NAFLD with other causes of liver diseaseα and adiponectin level from baseline to at the end
Results:
patients (15.6%) were obese (BMI >30 kg/m
II DM, twelve patients (37.5%) were hypertension and twenty seven (84.4%) were dyslipidemia. There were no
baseline demographic differences between both groups. The mean changes of serum alanine, aspartate aminotransferase
and fasting plasma glucose levels difference significantly from baseline in the pentoxifylline group compared
to the placebo group. (ALT + 68.2 ± 40.7 vs. + 18.2± 34.2, p = 0.001; AST + 27.3 ± 20.4 vs. + 7.9 ± 19.8, p =
0.008; FBS + 9.1 ± 10.7 vs. - 0.7 ± 5.7, p = 0.003, respectively) The pentoxifylline groups showed more improvement
in BMI, waist/hip ratio and serum TNF-
Adinopectin levels were not changed significantly between both groups. There was no serious adverse events
occurred.
The 32 patients had a mean age of 48.9 ± 11.7 yr. Nineteen patients (59%) were male, Five2) with mean BMI 26.5 ± 3.2 kg/m2, Five patients (15.6%) were typeα, compared with the placebo groups, without any statistically significant.
Conclusions:
level among patients with NAFLD when compared to placebo.
Pentoxifylline therapy effectively achieved significant improvement in aminotransferase
[Thai J Gastroenterol 2007; 8(2): 57-64]
antilipogenic and anti-inflammatory effects, while TNF-
effects. The aims of this study are to determine the efficacy and safety of pentoxifylline, a TNF-
compare with placebo |
file/Thai-Journal-of-gastroenterology-vol-8-no-2-3060384.pdf